Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
13,253
archived clinical trials in
Arthritis

β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated:  4/11/2016
Novartis Investigator Site
mi
from
Clearwater, FL
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated: 4/11/2016
Novartis Investigator Site
mi
from
Clearwater, FL
Click here to add this to my saved trials
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated:  4/11/2016
Novartis Investigative Site
mi
from
Jupiter, FL
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated: 4/11/2016
Novartis Investigative Site
mi
from
Jupiter, FL
Click here to add this to my saved trials
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated:  4/11/2016
Novartis Investigative Site
mi
from
Decatur, GA
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated: 4/11/2016
Novartis Investigative Site
mi
from
Decatur, GA
Click here to add this to my saved trials
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated:  4/11/2016
Novartis Investigator Site
mi
from
Topeka, KA
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated: 4/11/2016
Novartis Investigator Site
mi
from
Topeka, KA
Click here to add this to my saved trials
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated:  4/11/2016
Novartis Investigative Site
mi
from
Wichita, KA
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated: 4/11/2016
Novartis Investigative Site
mi
from
Wichita, KA
Click here to add this to my saved trials
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated:  4/11/2016
Novartis Investigative Site
mi
from
Metairie, LA
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated: 4/11/2016
Novartis Investigative Site
mi
from
Metairie, LA
Click here to add this to my saved trials
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated:  4/11/2016
Novartis Investigative Site
mi
from
Opelousas, LA
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated: 4/11/2016
Novartis Investigative Site
mi
from
Opelousas, LA
Click here to add this to my saved trials
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated:  4/11/2016
Novartis Investigative Site
mi
from
Flint, MI
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated: 4/11/2016
Novartis Investigative Site
mi
from
Flint, MI
Click here to add this to my saved trials
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated:  4/11/2016
Novartis Investigative Site
mi
from
Troy, MI
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated: 4/11/2016
Novartis Investigative Site
mi
from
Troy, MI
Click here to add this to my saved trials
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated:  4/11/2016
Novartis Investigative Site
mi
from
Jackson, MS
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated: 4/11/2016
Novartis Investigative Site
mi
from
Jackson, MS
Click here to add this to my saved trials
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated:  4/11/2016
Novartis Investigative Site
mi
from
Missoula, MT
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated: 4/11/2016
Novartis Investigative Site
mi
from
Missoula, MT
Click here to add this to my saved trials
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated:  4/11/2016
Novartis Investigative Site
mi
from
Freehold, NJ
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated: 4/11/2016
Novartis Investigative Site
mi
from
Freehold, NJ
Click here to add this to my saved trials
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated:  4/11/2016
Novartis Investigative Site
mi
from
Hickory, NC
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated: 4/11/2016
Novartis Investigative Site
mi
from
Hickory, NC
Click here to add this to my saved trials
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated:  4/11/2016
Novartis Investigative Site
mi
from
Dayton, OH
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated: 4/11/2016
Novartis Investigative Site
mi
from
Dayton, OH
Click here to add this to my saved trials
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated:  4/11/2016
Novartis Investigative Site
mi
from
Willoughby Hills, OH
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated: 4/11/2016
Novartis Investigative Site
mi
from
Willoughby Hills, OH
Click here to add this to my saved trials
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated:  4/11/2016
Novartis Investigational Site
mi
from
Charleston, SC
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated: 4/11/2016
Novartis Investigational Site
mi
from
Charleston, SC
Click here to add this to my saved trials
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated:  4/11/2016
Novartis Investigative Site
mi
from
Columbia, SC
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated: 4/11/2016
Novartis Investigative Site
mi
from
Columbia, SC
Click here to add this to my saved trials
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated:  4/11/2016
Novartis Investigative Site
mi
from
Varnville, SC
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated: 4/11/2016
Novartis Investigative Site
mi
from
Varnville, SC
Click here to add this to my saved trials
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated:  4/11/2016
Novartis Investigative Site
mi
from
Bristol, TN
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated: 4/11/2016
Novartis Investigative Site
mi
from
Bristol, TN
Click here to add this to my saved trials
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated:  4/11/2016
Novartis Investigative Site
mi
from
Clarksville, TN
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated: 4/11/2016
Novartis Investigative Site
mi
from
Clarksville, TN
Click here to add this to my saved trials
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated:  4/11/2016
Novartis Investigative Site
mi
from
Johnson City, TN
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated: 4/11/2016
Novartis Investigative Site
mi
from
Johnson City, TN
Click here to add this to my saved trials
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated:  4/11/2016
Novartis Investigative Site
mi
from
Danville, VA
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated: 4/11/2016
Novartis Investigative Site
mi
from
Danville, VA
Click here to add this to my saved trials
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated:  4/11/2016
Novartis Investigative Site
mi
from
Newport News, VA
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated: 4/11/2016
Novartis Investigative Site
mi
from
Newport News, VA
Click here to add this to my saved trials
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated:  4/11/2016
Novartis Investigative Site
mi
from
Darlinghurst,
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective
Status: Enrolling
Updated: 4/11/2016
Novartis Investigative Site
mi
from
Darlinghurst,
Click here to add this to my saved trials
Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA
Improved Understanding of the Biology and Use of TNF Inhibition in Children With JIA
Status: Enrolling
Updated:  4/13/2016
Children's Hospital of Alabama
mi
from
Birmingham, AL
Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA
Improved Understanding of the Biology and Use of TNF Inhibition in Children With JIA
Status: Enrolling
Updated: 4/13/2016
Children's Hospital of Alabama
mi
from
Birmingham, AL
Click here to add this to my saved trials
Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA
Improved Understanding of the Biology and Use of TNF Inhibition in Children With JIA
Status: Enrolling
Updated:  4/13/2016
Phoenix Children's Hospital
mi
from
Phoenix, AZ
Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA
Improved Understanding of the Biology and Use of TNF Inhibition in Children With JIA
Status: Enrolling
Updated: 4/13/2016
Phoenix Children's Hospital
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA
Improved Understanding of the Biology and Use of TNF Inhibition in Children With JIA
Status: Enrolling
Updated:  4/13/2016
Arkansas Children's Hospital Research Institute
mi
from
Little Rock, AR
Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA
Improved Understanding of the Biology and Use of TNF Inhibition in Children With JIA
Status: Enrolling
Updated: 4/13/2016
Arkansas Children's Hospital Research Institute
mi
from
Little Rock, AR
Click here to add this to my saved trials
Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA
Improved Understanding of the Biology and Use of TNF Inhibition in Children With JIA
Status: Enrolling
Updated:  4/13/2016
Connecticut Children's Medical Center
mi
from
Hartford, CT
Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA
Improved Understanding of the Biology and Use of TNF Inhibition in Children With JIA
Status: Enrolling
Updated: 4/13/2016
Connecticut Children's Medical Center
mi
from
Hartford, CT
Click here to add this to my saved trials
Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA
Improved Understanding of the Biology and Use of TNF Inhibition in Children With JIA
Status: Enrolling
Updated:  4/13/2016
Childrens National Medical Center
mi
from
Washington,
Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA
Improved Understanding of the Biology and Use of TNF Inhibition in Children With JIA
Status: Enrolling
Updated: 4/13/2016
Childrens National Medical Center
mi
from
Washington,
Click here to add this to my saved trials
Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA
Improved Understanding of the Biology and Use of TNF Inhibition in Children With JIA
Status: Enrolling
Updated:  4/13/2016
Emory University School of Medicine
mi
from
Atlanta, GA
Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA
Improved Understanding of the Biology and Use of TNF Inhibition in Children With JIA
Status: Enrolling
Updated: 4/13/2016
Emory University School of Medicine
mi
from
Atlanta, GA
Click here to add this to my saved trials
Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA
Improved Understanding of the Biology and Use of TNF Inhibition in Children With JIA
Status: Enrolling
Updated:  4/13/2016
Comer Children's Hospital University of Chicago
mi
from
Chicago, IL
Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA
Improved Understanding of the Biology and Use of TNF Inhibition in Children With JIA
Status: Enrolling
Updated: 4/13/2016
Comer Children's Hospital University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA
Improved Understanding of the Biology and Use of TNF Inhibition in Children With JIA
Status: Enrolling
Updated:  4/13/2016
University of Louisville Research Foundation, Inc.
mi
from
Louisville, KY
Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA
Improved Understanding of the Biology and Use of TNF Inhibition in Children With JIA
Status: Enrolling
Updated: 4/13/2016
University of Louisville Research Foundation, Inc.
mi
from
Louisville, KY
Click here to add this to my saved trials
Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA
Improved Understanding of the Biology and Use of TNF Inhibition in Children With JIA
Status: Enrolling
Updated:  4/13/2016
Joseph M. Sanzari Children's Hospital
mi
from
Hackensack, NJ
Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA
Improved Understanding of the Biology and Use of TNF Inhibition in Children With JIA
Status: Enrolling
Updated: 4/13/2016
Joseph M. Sanzari Children's Hospital
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA
Improved Understanding of the Biology and Use of TNF Inhibition in Children With JIA
Status: Enrolling
Updated:  4/13/2016
Children's Hospital at Montefiore
mi
from
Bronx, NY
Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA
Improved Understanding of the Biology and Use of TNF Inhibition in Children With JIA
Status: Enrolling
Updated: 4/13/2016
Children's Hospital at Montefiore
mi
from
Bronx, NY
Click here to add this to my saved trials
Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA
Improved Understanding of the Biology and Use of TNF Inhibition in Children With JIA
Status: Enrolling
Updated:  4/13/2016
Cohen Children's Medical Center of NY
mi
from
New Hyde Park, NY
Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA
Improved Understanding of the Biology and Use of TNF Inhibition in Children With JIA
Status: Enrolling
Updated: 4/13/2016
Cohen Children's Medical Center of NY
mi
from
New Hyde Park, NY
Click here to add this to my saved trials
Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA
Improved Understanding of the Biology and Use of TNF Inhibition in Children With JIA
Status: Enrolling
Updated:  4/13/2016
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA
Improved Understanding of the Biology and Use of TNF Inhibition in Children With JIA
Status: Enrolling
Updated: 4/13/2016
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA
Improved Understanding of the Biology and Use of TNF Inhibition in Children With JIA
Status: Enrolling
Updated:  4/13/2016
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA
Improved Understanding of the Biology and Use of TNF Inhibition in Children With JIA
Status: Enrolling
Updated: 4/13/2016
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA
Improved Understanding of the Biology and Use of TNF Inhibition in Children With JIA
Status: Enrolling
Updated:  4/13/2016
Medical University of South Carolina
mi
from
Charleston, SC
Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA
Improved Understanding of the Biology and Use of TNF Inhibition in Children With JIA
Status: Enrolling
Updated: 4/13/2016
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA
Improved Understanding of the Biology and Use of TNF Inhibition in Children With JIA
Status: Enrolling
Updated:  4/13/2016
Children's Hospital of Wisconsin
mi
from
Milwaukee, WI
Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA
Improved Understanding of the Biology and Use of TNF Inhibition in Children With JIA
Status: Enrolling
Updated: 4/13/2016
Children's Hospital of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA
Improved Understanding of the Biology and Use of TNF Inhibition in Children With JIA
Status: Enrolling
Updated:  4/13/2016
Children's Hospital of Pittsburgh
mi
from
Pittsburgh, PA
Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA
Improved Understanding of the Biology and Use of TNF Inhibition in Children With JIA
Status: Enrolling
Updated: 4/13/2016
Children's Hospital of Pittsburgh
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated:  4/13/2016
Rheumatology Associates, PC
mi
from
Birmingham, AL
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated: 4/13/2016
Rheumatology Associates, PC
mi
from
Birmingham, AL
Click here to add this to my saved trials
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated:  4/13/2016
Rheumatology Associates Of North Alabama, P.C.
mi
from
Huntsville, AL
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated: 4/13/2016
Rheumatology Associates Of North Alabama, P.C.
mi
from
Huntsville, AL
Click here to add this to my saved trials
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated:  4/13/2016
Medvin Clinical Research
mi
from
Covina, CA
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated: 4/13/2016
Medvin Clinical Research
mi
from
Covina, CA
Click here to add this to my saved trials
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated:  4/13/2016
Desert Medical Advances
mi
from
Palm Desert, CA
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated: 4/13/2016
Desert Medical Advances
mi
from
Palm Desert, CA
Click here to add this to my saved trials
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated:  4/13/2016
San Diego Arthritis Medical Clinic
mi
from
San Diego, CA
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated: 4/13/2016
San Diego Arthritis Medical Clinic
mi
from
San Diego, CA
Click here to add this to my saved trials
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated:  4/13/2016
Millennium Research
mi
from
Ormond Beach, FL
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated: 4/13/2016
Millennium Research
mi
from
Ormond Beach, FL
Click here to add this to my saved trials
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated:  4/13/2016
The Arthritis Center
mi
from
Palm Harbor, FL
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated: 4/13/2016
The Arthritis Center
mi
from
Palm Harbor, FL
Click here to add this to my saved trials
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated:  4/13/2016
Klein & Associates MD, PA.
mi
from
Hagerstown, MD
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated: 4/13/2016
Klein & Associates MD, PA.
mi
from
Hagerstown, MD
Click here to add this to my saved trials
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated:  4/13/2016
Clinical Pharmacology Study Group
mi
from
Worcester, MA
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated: 4/13/2016
Clinical Pharmacology Study Group
mi
from
Worcester, MA
Click here to add this to my saved trials
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated:  4/13/2016
St. Paul Rheumatology, PA
mi
from
Eagan, MN
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated: 4/13/2016
St. Paul Rheumatology, PA
mi
from
Eagan, MN
Click here to add this to my saved trials